These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 11707973)

  • 1. [A newly designed system, "FC-UV-CDDP", and a study of its oncolytic effect].
    Shindoh T; Matsuura N; Sugitachi A; Saitoh K
    Gan To Kagaku Ryoho; 2001 Oct; 28(11):1534-7. PubMed ID: 11707973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A study of the oncolytic effect of a newly designed CDDP system on an experimental animal model with carcinomatous ascites].
    Shindoh T; Matsuura N; Sugitachi A; Saitoh K
    Gan To Kagaku Ryoho; 2002 Nov; 29(12):2195-8. PubMed ID: 12484035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A loco-regional cancer chemotherapy, using a fibrin clot as a drug carrier--the oncolytic effects and putative mechanisms].
    Sugitachi A; Kohayakawa K; Kawahara T; Shindo T
    Gan To Kagaku Ryoho; 1991 Aug; 18(11):1817-21. PubMed ID: 1877823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Loco-regional cancer chemotherapy with a new drug delivery system, "anticancer drug-fibrin clot"].
    Sugitachi A; Takatsuka Y; Numata N; Kawahara T; Hirata M; Kido T; Sakamoto I
    Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):2814-7. PubMed ID: 2782891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A newly designed anticancer tumor immunity drug delivery system.
    Sugitachi A; Shindo T; Matsuda Y; Sakamoto I
    ASAIO Trans; 1991; 37(3):M177-8. PubMed ID: 1751099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Injectable drug carriers with sustained release of cis-platinum].
    Sugitachi A; Kashiwaba M; Takagane A; Asahi H; Saitoh K; Yoshida Y; Shindoh T; Matsuura N
    Gan To Kagaku Ryoho; 2003 Oct; 30(11):1851-4. PubMed ID: 14619537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A novel fibrin clot with a sustained release of cis-platinum (CDDP)].
    Sugitachi A; Takagane A; Terashima M; Kashiwaba M; Shimada H; Asahi H; Saitoh K
    Gan To Kagaku Ryoho; 2000 Oct; 27(12):1861-4. PubMed ID: 11086431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A novel Cisplatin delivery system for malignant ascites-bearing mice-a basic experimentation].
    Itabashi T; Sugitachi A; Kimura Y; Ikeda M; Kumagai M; Matsuo T; Fujii H; Nishizuka S; Otsuka K; Koeda K; Sasaki A; Wakabayashi G
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2081-3. PubMed ID: 22202290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Novel dosage forms with a sustained release of aqueous cis-platinum].
    Sugitachi A; Kashiwaba M; Takagane A; Asahi H; Saito K; Yoshida Y; Shindo T; Matsuura N
    Gan To Kagaku Ryoho; 2004 Oct; 31(11):1758-60. PubMed ID: 15553706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experimental and clinical evaluation of cisplatin-containing microspheres as intraperitoneal chemotherapy for ovarian cancer.
    Sugiyama T; Kumagai S; Nishida T; Ushijima K; Matsuo T; Yakushiji M; Hyon SH; Ikada Y
    Anticancer Res; 1998; 18(4B):2837-42. PubMed ID: 9713471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A novel formulation of cisplatin (CDDP)].
    Sugitachi A; Kimura Y; Itabashi T; Noda H; Ishida K; Nishizuka S; Otsuka K; Kashiwaba M; Nitta H; Koeda K; Mizuno M; Sasaki A; Ikeda K; Takamori Y; Wakabayashi G
    Gan To Kagaku Ryoho; 2009 Nov; 36(12):2294-6. PubMed ID: 20037400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anticancer efficacy with cisplatin delivery systems].
    Sugitachi A; Kimura Y; Itabashi T; Ikeda M; Ishida K; Noda H; Matsuo T; Nishizuka S; Otsuka K; Koeda K; Sato A; Takahashi T; Wakabayashi G
    Gan To Kagaku Ryoho; 2010 Nov; 37(12):2274-6. PubMed ID: 21224545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A novel sustained release system for aqueous cis-platinum].
    Sugitachi A; Kashiwaba M; Takagane A; Asahi H; Saitoh K; Takahashi M; Nakajima H; Shindoh T; Matsuura N
    Gan To Kagaku Ryoho; 2002 Nov; 29(12):2191-4. PubMed ID: 12484034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Novel biodegradable materials for drug delivery systems (DDS)].
    Sugitachi A; Kashiwaba M; Shimada Y; Terashima M; Asahi H; Saitoh K; Yoshida Y
    Gan To Kagaku Ryoho; 2001 Oct; 28(11):1530-3. PubMed ID: 11707972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amifostine increases cure rate of cisplatin on ascites hepatoma 22 via selectively protecting renal thioredoxin reductase.
    Zhang J; Wang X; Lu H
    Cancer Lett; 2008 Feb; 260(1-2):127-36. PubMed ID: 18039557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. L- and D- methionine provide equivalent long term protection against CDDP-induced ototoxicity in vivo, with partial in vitro and in vivo retention of antineoplastic activity.
    Reser D; Rho M; Dewan D; Herbst L; Li G; Stupak H; Zur K; Romaine J; Frenz D; Goldbloom L; Kopke R; Arezzo J; Van De Water T
    Neurotoxicology; 1999 Oct; 20(5):731-48. PubMed ID: 10591510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Chitin/cisplatin--an adhesive anticancer drug].
    Sugitachi A; Otsuka K; Itabashi T; Chiba T; Kimura Y; Sasaki A; Ikeda K; Uesugi N; Takamori Y; Kurozumi S; Mori T; Wakabayashi G
    Gan To Kagaku Ryoho; 2008 Nov; 35(12):2021-3. PubMed ID: 19106510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apoptosis-inducing activity of cisplatin (CDDP) against human hepatoma and oral squamous cell carcinoma cell lines.
    Okamura M; Hashimoto K; Shimada J; Sakagami H
    Anticancer Res; 2004; 24(2B):655-61. PubMed ID: 15161008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A novel anticancer drug delivery system -DAC-70/CDDP].
    Sugitachi A; Otsuka K; Fujisawa K; Itabashi T; Akiyama Y; Sasaki A; Ikeda K; Yoshida Y; Takamori Y; Kurozumi S; Mori T; Wakabayashi G
    Gan To Kagaku Ryoho; 2007 Nov; 34(12):2159-61. PubMed ID: 18219931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.